Cariprazin: New hope for schizophrenia patients in Europe!

Cariprazin: New hope for schizophrenia patients in Europe!

Madrid, Spanien - At the 33rd annual conference of the European Psychiatric Society (EPA), which took place in Madrid from April 5 to April 8, Gedeon Richter PLC presented current findings on Cariprazine. These new analyzes show that Cariprazine is a promising treatment option for patients with schizophrenia and simultaneous cannabis consumption. The effectiveness of the drug was demonstrated using various scientific posters presented during the conference. In particular, it was pointed out to the results of a six -month observation study, which highlights the positive effects of cariprazine in patients with dual schizophrenia and cannabis consumption disorder and underpins the effectiveness of the drug. Cariprazine also shows that it significantly reduces the risk of relapse regardless of the gender of the patient compared to placebo.

The first poster assessed the effectiveness of Cariprazine in patients with dual schizophrenia and cannabis consumption disorder. The results of a six -month observation study showed a clear effectiveness of the medication. The second poster made it clear that the gender of the patient has no significant influence on the risk of relapse. Cariprazine lowers the risk of relapse in both genders compared to placebo.

effect on negative symptoms

A third poster focused on the negative symptoms in female patients during their hospital stay. The results show that Cariprazine leads to a significant decrease in these symptoms in both mono and poly therapy. This is particularly relevant in the context of the current discussion about the challenges in the treatment of negative symptoms in schizophrenia.

In addition, a fourth poster was presented that summarizes knowledge about the combination of cariprazine with clozapine. This augmentation strategy proves to be promising for patients with treatment -resistant schizophrenia, especially with regard to the relief of negative symptoms. The discussion about the advantages of third -generation antipsychotics, which includes Cariprazine, was illuminated by a scientific symposium entitled "Partial Activity, Full Impact: Innovations in Schizophrene Liebung.

statistical relevance and study situation

Cariprazin not only proven itself in observation studies, but also in a systematic review that included 12 studies with a total of 6477 patients. This review, as reported by the researchers in [PMC], emphasizes that Cariprazin significantly reduces global clinical severity and provides better results in higher doses. The improvement extends to psychotic, depressed, manic and anxiety symptomatic phenomena. Cariprazine represent such results as a potential cornerstone in the treatment of schizophrenia and bipolar disorder.

The discussion about the combination of antipsychotics is also supplemented by the results of the combine study. This examines the emerging advantages of the combination of clozapine with cariprazine, especially for therapy -resistant patients. It becomes clear that the approach of antipsychotic combination treatment is promising and should be further examined in clinical practice.

Cariprazin has been approved in 67 countries worldwide and has already reached around 1.7 million patients since its introduction to Europe and the United States. His broad applicability and the positive results in clinical studies give this drug an important role in psychiatry.